Fate Therapeutics (FATE) Prices 8.6M Share Offering at $17.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
After-Hours Movers 09/11: (REVG) (CHGG) (BLKB) Higher; (TLRD) (CELP) (OXM) Lower (more...)
September 11, 2019 5:50 PM EDTToday's After-Hours Movers
Tailored Brands (NYSE: TLRD) 25.4% LOWER; reported Q2 EPS of $0.82, $0.08 better than the analyst estimate of $0.74. Revenue for the quarter came in at $789.5 million versus the consensus estimate of $789.19 million. Tailored Brands sees Q3 2019 EPS of $0.40-$0.45, versus the consensus of $0.88. Tailored Brands to suspends quarterly cash dividend starting in Q4 2019. Company to redeploy capital to accelerated debt repayment and share repurchases.
Celsius Holdings,... More
Fate Therapeutics (FATE) Plans Offering of Common Stock
September 11, 2019 4:02 PM EDTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund... More
